Zobrazeno 1 - 10
of 26 372
pro vyhledávání: ''
Autor:
Chiara Finocchiaro, Simona Toscano, Salvatore Lo Fermo, Francesco Patti, Enrico Millefiorini, Eleonora Sgarlata, Clara Grazia Chisari
Publikováno v:
Current Neuropharmacology. 20:1978-1987
Background: Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic infection caused by John Cunningham virus (JCV) reactivation, potentially associated with natalizumab (NTZ) treatment for Multiple Sclerosis (MS). The anti-JCV antibodie
Publikováno v:
Exp Clin Psychopharmacol
Experimental and clinical psychopharmacology, vol 30, iss 3
Experimental and clinical psychopharmacology, vol 30, iss 3
Research on nicotine metabolism has primarily focused on white adults. This study examined associations between nicotine metabolism, tobacco use, and demographic characteristics among Alaska Native adults who smoke cigarettes. Participants (N = 244)
Autor:
Joanna Parkinson, David W. Boulton, Weifeng Tang, Robert C. Penland, Bengt Hamrén, Melin J, Dinko Rekić
Publikováno v:
The Journal of Clinical Pharmacology. 62:1227-1235
Aim: Dapagliflozin improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) and is approved in European and Japanese patients with type 1 diabetes mellitus (T1DM) with inadequate glycaemic control. The objectives of this work were
Publikováno v:
Cannabis Cannabinoid Res
INTRODUCTION: Cannabidiol (CBD) is a major cannabinoid extracted from Cannabis sativa with no abuse potential. Data from recent rodent studies suggest that amelioration of alcohol-motivated behaviors may be one of the numerous pharmacological effects
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Wouter ten Voorde, Robert Rissmann, Michelle Osse, Manon A. A. Jansen, G. Feiss, Edwin Florencia, Mascha Schoonakker, Floris C. van Hindevoort, Matthijs Moerland, Erik Lubberts, Pieter W Hameeteman, Thomas P. Buters, Jeffrey Damman, Amit Patel, Iris M. E. Jansen, Marieke L. de Kam, Jacobus Burggraaf, Simon Yona, Derek W. Gilroy, Hendrika W. Grievink
Publikováno v:
British Journal of Clinical Pharmacology, 88(2), 680-690. Wiley-Blackwell Publishing Ltd
British Journal of Clinical Pharmacology, 88(2), 680-690. WILEY
British Journal of Clinical Pharmacology, 88(2), 680-690. WILEY
Aims: Whereas intravenous administration of Toll-like receptor 4 ligand lipopolysaccharide (LPS) to human volunteers is frequently used in clinical pharmacology studies, systemic use of LPS has practical limitations. We aimed to characterize the intr
Publikováno v:
Experimental and Clinical Psychopharmacology, 30, 73-81
Experimental and Clinical Psychopharmacology, 30, 1, pp. 73-81
Experimental and Clinical Psychopharmacology, 30, 1, pp. 73-81
Shortly after young adolescents initiate alcohol use, we investigated whether (1) drinking motives are associated with current alcohol use and binge drinking, (2) motives predict these alcohol outcomes 6 months later, and (3) alcohol outcomes predict
Autor:
Helen Carnaghan, Joanne Bal, Rab K. Prinjha, Jackie C. Bloomer, Jack A. Brown, Peter Ernest Soden, Palwinder K. Mander, Sarah J Hopkins, João Joaquim Oliveira, Lars Erwig, William A. Fahy, Yi Cui, Shruti Daga, Bill Davis, Monica Simeoni, Disala Fernando, Peter Williams, Gabriel K. Wong, Edward Banham-Hall
Publikováno v:
British Journal of Clinical Pharmacology. 88:2140-2155
GSK3358699 is a mononuclear myeloid-targeted bromodomain and extra-terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro. This phase 1, randomized, first-in-human study evaluated the safety, pharmacokinetics, and
Autor:
Michael J. Hanley, Karthik Venkatakrishnan, Paul M. Diderichsen, Narayana I. Narasimhan, Shouryadeep Srivastava, Neeraj Gupta
Publikováno v:
The Journal of Clinical Pharmacology. 62:555-567
The BCR-ABL1 inhibitor ponatinib is approved for the treatment of adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia, including those with the T315I mutation. We report a population pharmacokinetic (
Publikováno v:
CNS Neuroscience & Therapeutics
Aims The α2‐adrenergic receptor (α2‐AR) agonists have been shown to be effective in the treatment of various pain. For example, dexmedetomidine (DEX), a selective α2A‐AR agonist, can be used for peripheral analgesia. However, it is not yet f